Genzyme dumps Cerezyme material

To minimize risk to its newly cleaned manufacturing plant and to ensure that new supplies of the Gaucher-disease treatment Cerezyme will be available by the end of this year, Genzyme is discarding some 80 percent of the remaining in-process material. "We could not take the risk of processing material that has any possibility of re-contaminating the plant and setting back our ability to supply Cerezyme," says CEO Henri Termeer, in a statement. The company expects to begin releasing new material in November. Release

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.